D
Daré Bioscience, Inc. (DARE)
NCM – Real Time Price. Currency in USD
2.63
+0.11 (4.37%)
At close: May 12, 2026, 4:00 PM EDT
2.67
+0.04 (1.52%)
After-hours: May 12, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.63
+0.11 (4.37%)
At close: May 12, 2026, 4:00 PM EDT
2.67
+0.04 (1.52%)
After-hours: May 12, 2026, 7:53 PM EDT
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. David Friend Ph.D. | Chief Scientific Officer |
| Jennifer Kiang | Vice President of Corporate Affairs & Development |
| Mr. Mark Walters | Vice President of Operations |
| Ms. MarDee J. Haring-Layton | Chief Accounting Officer |
| Ms. Sabrina Martucci Johnson | CEO, President, Principal Financial Officer, Secretary & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | dare-20260501.htm |
| 2026-04-28 | DEFA14A | defa14a2026additionalmater.htm |
| 2026-04-22 | 8-K | form8-k.htm |
| 2026-04-20 | 8-K | dare-20260417.htm |
| 2026-04-17 | PRE 14A | dare-20260417.htm |
| 2026-04-17 | 8-K | dare-20260416.htm |
| 2026-04-13 | 8-K | dare-20260410.htm |
| 2026-03-30 | 1-A POS | |
| 2026-03-26 | 8-K | form8-k.htm |
| 2026-03-26 | 10-K | dare-20251231.htm |